The Trump administration’s point-of-sale rebate proposal could bolster value-centered competition, Deloitte Vice Chairman and life science chief Greg Reh says.
According to an InsideHealthPolicy report, Reh said assessing a drug’s effectiveness against alternative treatments could enable drugmakers to make their case for formulary placement without rebates in the mix.
To read the full article on InsideHealthPolicy, click here. (Paid subscription required)
